199 related articles for article (PubMed ID: 22904106)
1. 14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival.
Murata T; Takayama K; Urano T; Fujimura T; Ashikari D; Obinata D; Horie-Inoue K; Takahashi S; Ouchi Y; Homma Y; Inoue S
Clin Cancer Res; 2012 Oct; 18(20):5617-27. PubMed ID: 22904106
[TBL] [Abstract][Full Text] [Related]
2. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
3. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
4. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
[TBL] [Abstract][Full Text] [Related]
5. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
Jalava SE; Urbanucci A; Latonen L; Waltering KK; Sahu B; Jänne OA; Seppälä J; Lähdesmäki H; Tammela TL; Visakorpi T
Oncogene; 2012 Oct; 31(41):4460-71. PubMed ID: 22266859
[TBL] [Abstract][Full Text] [Related]
6. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.
Takayama K; Tsutsumi S; Katayama S; Okayama T; Horie-Inoue K; Ikeda K; Urano T; Kawazu C; Hasegawa A; Ikeo K; Gojyobori T; Ouchi Y; Hayashizaki Y; Aburatani H; Inoue S
Oncogene; 2011 Feb; 30(5):619-30. PubMed ID: 20890304
[TBL] [Abstract][Full Text] [Related]
7. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.
Mink SR; Hodge A; Agus DB; Jain A; Gross ME
Prostate; 2010 Aug; 70(11):1201-10. PubMed ID: 20564426
[TBL] [Abstract][Full Text] [Related]
8. Molecular regulation of androgen action in prostate cancer.
Dehm SM; Tindall DJ
J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
[TBL] [Abstract][Full Text] [Related]
9. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
10. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
14. Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression.
Dryhurst D; McMullen B; Fazli L; Rennie PS; Ausió J
Cancer Lett; 2012 Feb; 315(1):38-47. PubMed ID: 22055461
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
Zolochevska O; Figueiredo ML
Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
[TBL] [Abstract][Full Text] [Related]
16. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
Kobayashi T; Shimizu Y; Terada N; Yamasaki T; Nakamura E; Toda Y; Nishiyama H; Kamoto T; Ogawa O; Inoue T
Prostate; 2010 Jun; 70(8):866-74. PubMed ID: 20127734
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
18. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
Jia L; Coetzee GA
Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
[TBL] [Abstract][Full Text] [Related]
20. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
